Cheesegrater;
From the info posted on clinicaltrials.gov:
“Viral load equal to or less than 800.000 IU/mL.” is listed in the inclusion criteria.
http://clinicaltrials.gov/ct2/show/NCT00563173?term=hcv&intr=ChronVac-C&rank=1
Bill
Sounds promising, but I visited those 2 links first mentioned.
There is no mention of starting/baseline viral load in those who responded.
Were the starting VL ridiculpously low to begin with?
Noted well with thanks. I was reading every articles with big hope ..you know... every morning I open my mail box with hope someone is going to tell me products good news for my wife... something like that...
Thanks indeed Bill and all, enlightening me and still giving us hope...
Aung
I was referring to the first link you posted which does make reference to just 2 out of 2. Haven't had time to carefully review the second link. If it turns out it's the same study, then I'd like to blame it on sloppy abstract writing as opposed to sloppy reading :)
---------
Bill: It looks as though our old friend Karin Lindahl is listed as a sub-investigator in these trials :o).
-------------
You don't think she secretly laced the vaccine with riba, do you ?????
Aung;
This is a very small ‘phase 1-2a’ trial; it will be interesting to see results if the drug proceeds forward to larger populations in phase 2 and 3. As far as practical use for your wife, it can take drugs like these 8-10 years or more to actually reach market; we know this from our experience with other products. The testing and approval process for western medicine is very cautious in nature.
For more information on clinical trials in the US as well as internationally:
http://clinicaltrials.gov/ct2/search
as well as more on CHRONVAC-C from the same site:
http://clinicaltrials.gov/ct2/show/NCT00563173?term=hcv&intr=ChronVac-C&rank=1
Take care—
Bill
~~~~~~~~~~~~~~~~~~~~~~~
Jim—
It looks as though our old friend Karin Lindahl is listed as a sub-investigator in these trials :o).
"two of three subjects demonstrated reductions in viral load of 93% and 99.7%. Previously reported middle dose cohort results demonstrated an 87% and 98% reduction in HCV in two of three subjects"
This says 2 out of 3. Unless I am missing something. Even 2 out of three is very promising....I agree. Just wondering what the 3rd one was.
Thanks for the comment...
"mechanism toxicity" should have read "mechanism and toxicity"
Potentially VERY exciting. Just imagine a short course of Peg thrown in either during or after. The vaccine approach has always seemed the most promising both in terms of mechanism toxcicity. BTW there was no "third" person as I read it. Only two reports are in and this is from the mid-dose group. The high-dose group may even do better!!!
I need more responses from you guys as people from our country Burma (Myanmar) are lack of these knowledge... we easily want to believe in something..
Thank you guys..
The report says there was a good response in 2 out of the 3 patients. But they don't say what the response was in the 3rd patient. Why not ??
A little skeptical.
thanks for sharing this, it's looks very promising doesn't it! It would be a Godsend if this to work on the already infected as they claim it is!!
mb